HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ulrike I Attenberger Selected Research

gadobutrol

1/2021Intraindividual Comparison of Compressed Sensing-Accelerated Cartesian and Radial Arterial Phase Imaging of the Liver in an Experimental Tumor Model.
5/2018The impact of injector-based contrast agent administration in time-resolved MRA.
11/2012Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study.
9/2012Time-resolved MR angiography of renal artery stenosis in a swine model at 3 Tesla using gadobutrol with digital subtraction angiography correlation.
6/2012Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography.
12/2010Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
3/2010Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
5/2009Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ulrike I Attenberger Research Topics

Disease

7Body Weight (Weight, Body)
05/2018 - 06/2008
4Neoplasms (Cancer)
01/2021 - 05/2009
3Pathologic Constriction (Stenosis)
09/2013 - 12/2010
3Glioma (Gliomas)
12/2010 - 05/2009
2Liver Cirrhosis (Hepatic Cirrhosis)
01/2022 - 01/2021
2Prostatic Neoplasms (Prostate Cancer)
01/2018 - 03/2014
2Renal Artery Obstruction (Renal Artery Stenosis)
09/2012 - 06/2012
1Sarcopenia
05/2022
1Hemorrhage
12/2021
1Bronchitis
01/2021
1Rectal Neoplasms (Rectal Cancer)
01/2017
1Hepatocellular Carcinoma (Hepatoma)
08/2016
1Kidney Diseases (Kidney Disease)
02/2016
1Inflammation (Inflammations)
02/2016
1Myocardial Ischemia (Ischemic Heart Diseases)
09/2013
1Pulmonary Embolism
08/2013
1Peripheral Arterial Disease
11/2012
1Hypoxia (Hypoxemia)
05/2012
1Aneurysm (Aneurysms)
10/2011
1Peripheral Arterial Occlusive Disease 1
12/2010
1Brain Neoplasms (Brain Tumor)
05/2009

Drug/Important Bio-Agent (IBA)

8gadobutrolIBA
01/2021 - 05/2009
6Contrast MediaIBA
05/2018 - 06/2008
4GadoliniumIBA
09/2012 - 05/2009
3Biomarkers (Surrogate Marker)IBA
05/2022 - 01/2021
3gadoterate meglumineIBA
06/2012 - 05/2009
2PlasticsIBA
01/2021 - 12/2010
2IodineIBA
08/2013 - 05/2012
2gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetateIBA
11/2012 - 06/2012
2Gadolinium DTPA (Magnevist)FDA Link
03/2010 - 05/2009
1GelatinIBA
12/2021
1gadolinium ethoxybenzyl DTPAFDA Link
01/2021
1Pharmaceutical PreparationsIBA
10/2018
1Therapeutic UsesIBA
08/2016
1Ferrosoferric Oxide (Magnetite)FDA Link
02/2016
1Choline (Choline Chloride)IBA
03/2014
1Adenosine (Adenocard)FDA LinkGeneric
09/2013
14- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA
08/2013
1iodixanol (Visipaque)FDA Link
05/2012
1iopromide (Ultravist)FDA Link
05/2012
1gadodiamide (Omniscan)FDA Link
12/2010

Therapy/Procedure

3Therapeutics
10/2018 - 10/2011
1Extracorporeal Membrane Oxygenation
01/2021
1Nephrotomy
10/2018
1Prostatectomy (Retropubic Prostatectomy)
01/2018
1Radiotherapy
01/2018
1Intravenous Administration
02/2016
1Catheters
06/2012
1Cannula
12/2010